Alx Oncology Holdings Inc (NASDAQ: ALXO) kicked off on Friday, up 13.59% from the previous trading day, before settling in for the closing price of $1.03. Over the past 52 weeks, ALXO has traded in a range of $0.40-$2.59.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -32.29%. While this was happening, its average annual earnings per share was recorded 36.79%. With a float of $37.38 million, this company’s outstanding shares have now reached $53.51 million.
Alx Oncology Holdings Inc (ALXO) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Alx Oncology Holdings Inc is 30.04%, while institutional ownership is 36.21%. The most recent insider transaction that took place on Aug 18 ’25, was worth 58,402. In this transaction Chief Financial Officer of this company bought 75,000 shares at a rate of $0.78, taking the stock ownership to the 75,000 shares. Before that another transaction happened on Aug 15 ’25, when Company’s SVP, FINANCE AND CAO sold 611 for $0.64, making the entire transaction worth $391. This insider now owns 89,198 shares in total.
Alx Oncology Holdings Inc (ALXO) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.58 earnings per share (EPS), higher than consensus estimate (set at -0.66) by 0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 36.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 32.45% during the next five years compared to -32.29% drop over the previous five years of trading.
Alx Oncology Holdings Inc (NASDAQ: ALXO) Trading Performance Indicators
Take a look at Alx Oncology Holdings Inc’s (ALXO) current performance indicators. Last quarter, stock had a quick ratio of 4.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.20, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.08 in one year’s time.
Technical Analysis of Alx Oncology Holdings Inc (ALXO)
Compared to the last year’s volume of 0.87 million, its volume of 5.18 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 81.59%.
During the past 100 days, Alx Oncology Holdings Inc’s (ALXO) raw stochastic average was set at 97.46%, which indicates a significant increase from 96.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1134 in the past 14 days, which was higher than the 0.0570 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5731, while its 200-day Moving Average is $0.9368. Nevertheless, the first resistance level for the watch stands at $1.2300 in the near term. At $1.2900, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.3900. If the price goes on to break the first support level at $1.0700, it is likely to go to the next support level at $0.9700. Now, if the price goes above the second support level, the third support stands at $0.9100.
Alx Oncology Holdings Inc (NASDAQ: ALXO) Key Stats
The company with the Market Capitalisation of 62.65 million has total of 53,551K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -134,850 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -25,950 K.
